Efficacy News and Research

RSS

Cognitive-behavioural therapy can reduce pain during intercourse

One in five women experience pain during intercourse. The latest edition of the Diagnostic and Statistical Manual of Mental Disorders, the bible of American psychiatrists, lists it under "genito-pelvic pain or penetration disorder."

26 May 2021

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

A new study aims to identify antibody-based biomarkers associated with the humoral immune response that could be a standard CoP candidate for COVID-19. Further, standardization of research methods to measure these biomarkers has also been conducted.

25 May 2021

Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency

A team of international scientists recently conducted a randomized clinical trial to assess the safety and efficacy profiles of a novel probiotic formulation in symptomatic coronavirus disease 2019 (COVID-19) patients. The findings indicate that the probiotic formulation is highly effective in reducing symptom severity in COVID-19 patients without causing any adverse events.

25 May 2021

Newly identified small molecule can be used to rejuvenate the brain, counteract memory loss

Alzheimer's disease is the main cause of dementia and current therapeutic strategies cannot prevent, slow down or cure the pathology.

25 May 2021

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

DEFINE: Trial designed to test repurposed treatments in patients with COVID-19

A team of scientists from the United Kingdom has designed an experimental medicine trial to evaluate the safety/tolerability, and efficacy profiles of a panel of candidate repurposed therapies in coronavirus disease 2019 (COVID-19) patients. A detailed outline of the trial is currently available on the medRxiv* preprint server.

25 May 2021

Do mixed COVID-19 vaccines provide immunity?

The initial results of the CombivacS trial found that the antibody levels in individuals increased by 150 times when the Pfizer messenger ribonucleic acid (mRNA) vaccine was given after a first dose of the AstraZeneca severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, with only mild common side effects.

24 May 2021

Researchers take steps to standardize correlates of protection against SARS-CoV-2

Antibodies, Antibody, Assay, Coronavirus, Efficacy, Healthcare, Pandemic, Protein, Receptor, Research, Vaccine, Virus, Coronavirus Disease COVID-19,

24 May 2021

Could an antiviral mouthwash using silver nanoparticles prevent COVID-19?

In a recent study by researchers in Mexico, Russia and Spain, silver nanoparticles (AgNPs) were found to inhibit SARS-CoV-2 in healthcare workers. They propose a non-pharmaceutical public health intervention consisting of mouthwash and nose rinse with an AgNPs solution to reduce morbidity among healthcare personnel exposed to the SARS-CoV-2 virus.

24 May 2021

Are COVID-19 medications safe in pregnancy?

Most medications being tested today in clinical trials for the treatment of coronavirus disease 2019 (COVID-19) have been repurposed from other indications. These are typically not tested in pregnant women. A new study, published in the journal PLOS ONE, summarizes what is known about the safety of these drugs in this group.

24 May 2021

Study: Four-month regimen of anti-TB drugs works just as well as standard regimen

A new four-month regimen of anti-TB drugs that includes rifapentine and moxifloxacin works just as well as the standard six-month regimen, according to a study.

24 May 2021

Reduced levels of leptin are linked to poor vaccine responses in general population

Reduced levels of a metabolic hormone known as leptin is linked to poor vaccine antibody responses in the general population, a University of Queensland study has found.

24 May 2021

Could saffron be an effective supplement for helping manage COVID-19?

A new study, published in the journal Cell Press, explores the potential use of saffron (Crocus sativus L.) as a drug supplement for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19).

24 May 2021

Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy

The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice. The study is currently available on the bioRxiv* preprint server.

24 May 2021

Researchers identify factors influencing vaccine hesitancy in USA

A team of scientists from the Washington University, in St. Louis, USA, has recently conducted a survey to analyze factors responsible for coronavirus disease 2019 (COVID-19) vaccination hesitancy among US citizens.

24 May 2021

Genetically engineered intestinal organoids reveal potential treatment targets against SARS-CoV-2

Using CRISPR/Cas9 and human intestinal organoids to study genes implicated in the biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), researchers from the Netherlands identified a specific serine protease (TMPRSS2) as an attractive pan-coronavirus therapeutic target. Their exciting findings are available in a study currently available on the bioRxiv* preprint server.

24 May 2021

Proof that face masks reduce SARS-CoV-2 transmission

Researchers in Germany and China have conducted a study analyzing the efficacy of face masks in mitigating the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

24 May 2021

Computationally designed peptide blocks the entry of SARS-CoV, SARS-CoV-2, and MERS-CoV

In order to develop effective antiviral drugs, scientists design active molecules based on their structures that can prevent or disrupt the specific viral-receptor binding - this is an effective strategy to prevent the virus from entering the host.

23 May 2021

SARS-CoV-2 B.1.1.7 and B.1.351 variants exhibit enhanced affinity towards the ACE2 receptor

In a short correspondence paper recently uploaded to the Lancet by Ramanathan, Muthukumar et al. (May 19th, 2021) the affinity of labeled SARS-CoV-2 spike receptor-binding domain proteins sourced from each of these two variants of concern towards human angiotensin-converting enzyme 2 (ACE2) recombinant proteins is investigated using microscale thermophoresis, confirming the enhanced affinity towards the receptor observed in other studies.

22 May 2021

Efficacy News and Research

Cognitive-behavioural therapy can reduce pain during intercourse

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency

Newly identified small molecule can be used to rejuvenate the brain, counteract memory loss

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

DEFINE: Trial designed to test repurposed treatments in patients with COVID-19

Do mixed COVID-19 vaccines provide immunity?

Researchers take steps to standardize correlates of protection against SARS-CoV-2

Could an antiviral mouthwash using silver nanoparticles prevent COVID-19?

Are COVID-19 medications safe in pregnancy?

Study: Four-month regimen of anti-TB drugs works just as well as standard regimen

Reduced levels of leptin are linked to poor vaccine responses in general population

Could saffron be an effective supplement for helping manage COVID-19?

Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy

Researchers identify factors influencing vaccine hesitancy in USA

Genetically engineered intestinal organoids reveal potential treatment targets against SARS-CoV-2

Proof that face masks reduce SARS-CoV-2 transmission

Computationally designed peptide blocks the entry of SARS-CoV, SARS-CoV-2, and MERS-CoV

SARS-CoV-2 B.1.1.7 and B.1.351 variants exhibit enhanced affinity towards the ACE2 receptor

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News